China Approves First AI-Designed Drug for COVID-19 Treatment
China's National Medical Products Administration (NMPA) has approved an innovative class 1 drug, Mprosevir, developed using artificial intelligence for the first time. The drug is intended for treating mild to moderate COVID-19 in adults. The development process, from finding a promising compound to successful clinical trials, took just 3.5 years, significantly faster than the traditional 10 to 15 years. AI played a key role in selecting effective compounds from a database of 49 billion molecular compounds and optimizing the molecule's properties.12 sourcesSee all sources

